Інформація призначена тільки для фахівців сфери охорони здоров'я, осіб,
які мають вищу або середню спеціальну медичну освіту.


Підтвердіть, що Ви є фахівцем у сфері охорони здоров'я.

"News of medicine and pharmacy" Неврологія. Нейрохірургія. Психіатрія (703) 2019 (тематичний номер)

Back to issue

Оценка диагностической эффективности биомаркеров для инсульта

Authors: Мельник А.А., к.б.н., руководитель проекта специализированного медицинского центра «Оптима Фарм», г. Киев, Украина

Sections: Specialist manual

print version

Всемирная организация здравоохранения (ВОЗ) определяет инсульт как клинический синдром, характеризующийся быстро развивающимися признаками очаговых (двигательных, речевых, координантных, зрительных) или общемозговых (изменение сознания, головная боль, рвота и др.) нарушений функции головного мозга, которые сохраняются более 24 часов или приводят к смерти больного за более короткий промежуток времени вследствие причин цереброваскулярного происхождения. По данным ВОЗ, от инсульта в мире ежегодно умирает около 6,3 миллиона человек (10,8 % от общего числа смертей). Летальность при этой патологии занимает второе место, уступая лишь заболеваниям сердечно-сосудистой системы, и составляет 8 % среди мужчин, 16 % среди женщин; показатель инвалидизации составляет 3,2 на 1 тыс. населения, из ...


For the full article you need to subscribe to the magazine.


Bibliography

1. Johnson W., Onuma O., Owolabi M. et al. Stroke: a global response is needed. Bulletin of the Word Helath Organization. 2016. 94. 634-634A.

2. Lopez A.D., Mathers C.D., Ezzati M. et al. Global and regional burden of disease and risk factors, 2001: Systematic analysis of population health data. Lancet. 2006. 367. 1747-1757.

3. Royal College of Physicians Sentinel Stroke National Audit Programme (SSNAP). Stroke health economics: cost and cost-effectiveness analysis 2016.

4. Schutta H.S., Howe H.M. Seventeenth century concepts of ‘‘apoplexy’’ as reflected in Bonet’s ‘‘Sepulchretum’’. J. Hist. Neurosci. 2006. 15. 250-268.

5. Schutta H.S. Morgagni on apoplexy in De Sedibus: a historical perspective. J. Hist. Neurosci. 2009. 18. 1-24.

6. Sacco R., Kasner S., Broderick J. et al. An updated definition of stroke for the 21st Century: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013. 44. 2064-2089.

7. Allen C., Bayraktutan U. Risk factors for ischaemic stroke. Int. J. Stroke. 2008. 3 (2). 105-116.

8. Jickling G.C., Sharp F.R. Biomarker Panels in Ischemic Stroke. Stroke. 2015. Vol. 46. 915-920.

9. Eng L.F., Vanderhaeghen J.J., Bignami A. et al. An acidic protein isolated from fibrous astrocytes. Brain Res. 1971. 28. 351-354.

10. Schiff L., Hadker N., Weiser S. et al. A literature review of the feasibility of glial fi brillary acidic protein as a biomarker for stroke and traumatic brain injury. Mol. Diagn. Ther. 2012. 16. 79-92.

11. Foerch C., Pfeilschifter W., Zeiner P. et al. Glial fi brillary acidic protein in patients with symptoms of acute stroke: Diagnostic marker of cerebral hemorrhage. Nervenarzt. 2014. 85. 982-9.

12. Foerch C., Curdt I., Yan B. et al. Serum glial fi brillary acidic protein as a biomarker for intracerebral haemorrhage in patients with acute stroke. J. Neurol. Neurosurg. Psychiatry. 2006. 77. 181-4.

13. Unden J., Strandberg K., Malm J. et al. Explorative investigation of biomarkers of brain damage and coagulation system activation in clinical stroke differentiation. J. Neurol. 2009. 256. 72-7.

14. Ehrenreich H., Kästner A., Weissenborn K. et al. Circulating damage marker profi les support a neuroprotective effect of erythropoietin in ischemic stroke patients. Mol. Med. 2011. 17. 1306-10.

15. Dvorak F., Haberer I., Sitzer M. et al. Characterisation of the diagnostic window of serum glial fibrillary acidic protein for the differentiation of intracerebral haemorrhage and ischaemic stroke. Cerebrovasc. Dis. 2009. 27. 37-41.

16. Zetterberg H., Smith D.H., Blennow K. Biomarkers of mild traumatic brain injury in cerebrospinal fluid and blood. Nat. Rev. Neurol. 2013. 9 (4). 201-10.

17. Donato R. S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int. J. Biochem. Cell Biol. 2001. 33. 637-68.

18. Lam V., Albrecht M.A., Takechi R. et al. The serum concentration of the calcium binding protein s100b is positively associated with cognitive performance in older adults. Front. Aging Neurosci. 2013. 5. 61.

19. Elting J.W., de Jager A.E., Teelken A.W. et al. Comparison of serum S-100 protein levels following stroke and traumatic brain injury. J. Neurol. Sci. 2000. 181. 104-10.

20. Kapural M., Krizanac-Bengez L., Barnett G. et al. Serum S-100beta as a possible marker of blood-brain barrier disruption. Brain Res. 2002. 94C. 102-4.

21. Nash D.L., Bellolio M.F., Stead L.G. S100 as a marker of acute brain ischemia: A systematic review. Neurocrit. Care. 2008. 8(2). 301-7.

22. Chong Z.Z. S100B raises the alert in subarachnoid hemorrhage. Rev. Neurosci. 2016. 27 (7). 745-59.

23. Kellermann I., Kleindienst A., Hore N. et al. Early CSF and serum S100B concentrations for outcome prediction in traumatic brain injury and subarachnoid hemorrhage. Clin. Neurol. Neurosurg. 2016. 145. 79-83.

24. Undén J., Strandberg K., Malm J. et al. Explorative investigation of biomarkers of brain damage and coagulation system activation in clinical stroke differentiation. J. Neurol. 2009. Vol. 256, № 1. 72-77.

25. Montaner J., Mendioroz M., Delgado P. et al. Differentiating ischemic from hemorrhagic stroke using plasma biomarkers: The S100B/RAGE pathway. J. Proteomics. 2012. 75. 4758-65.

26. Matias-Guiu J., Martinez-Vazquez J., Ruibal A. et al. Myelin basic protein and creatine kinase BB isoenzyme as CSF markers of intracranial tumors and stroke. Acta Neurol. Scand. 1986. 73 (5). 461-465.

27. Aurell A., Rosengren L.E., Karlsson B. et al. Determination of S-100 and glial fibrillary acidic protein concentrations in cerebrospinal fluid after brain infarction. Stroke. 1991. 22 (10). 1254-1258.

28. Anand N., Stead L.G. Neuron-specific enolase as a marker for acute ischemic stroke: a systematic review. Cerebrovasc. Dis. 2005. 20 (4). 213-219.

29. Casmiro M., Maitan S., De Pasquale F. et al. Cerebrospinal fluid and serum neuron-specific enolase concentrations in a normal population. Eur. J. Neurol. 2005. 12 (5). 369-374.

30. Rosengren L.E., Karlsson J.E., Karlsson J.O. et al. Patients with myotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF. J. Neurochem. 1996. 67 (5). 2013-2018.

31. Furukawa H., Singh S.K., Mancusso R. et al. Subunit arrangement and function in NMDA receptors. Nature. 2005. 438. 185-92.

32. Gappoeva M.U., Izykenova G.A., Granstrem O.K. et al. Expression of NMDA neuroreceptors in experimental ischemia. Biochemistry (Mosc.). 2003. 68. 696-702.

33. Gascon S., Deogracias R., Sobrado M. et al. Transcription of the NR1 subunit of the N-methyl-D-aspartate receptor is down-regulated by excitotoxic stimulationand cerebral ischemia. J. Biol. Chem. 2005. 280. 35018-27.

34. Allard L., Lescuyer P., Burgess J. et al. ApoC-I and ApoC-III as potential plasmatic markers to distinguish between ischemic and hemorrhagic stroke. Proteomics. 2004. 4 (8). 2242-2251.

35. Bielewicz J., Kurzepa J., Czekajska-Chehab E. et al. Does serum Tau protein predict the outcome of patients with ischemic stroke? J. Mol. Neurosci. 2011. 43. 241-5.

36. Hesse C., Rosengren L., Andreasen N. et al. Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. Neurosci. Lett. 2001. 297. 187-90.

37. Hjalmarsson C., Bjerke M., Andersson B. et al. Neuronal and glia-related biomarkers in cerebrospinal fl uid of patients with acute ischemic stroke. J. Cent. Nerv. Syst. Dis. 2014. 6. 51-8.

38. Sotgiu S., Zanda B., Marchetti B. et al. Inflammatory biomarkers in blood of patients with acute brain ischemia. Eur. J. Neurol. 2006. 13 (5). 505-513.

39. Kuhlmann C.R., Librizzi L., Closhen D. et al. Mechanisms of C-reactive protein-induced blood-brain barrier disruption. Stroke. 2009. 40 (4). 1458-1466.

40. Smith C.J., Emsley H.C., Gavin C.M. et al. Peak plasma interleukin-6 and other peripheral markers of inflammation in the first week of ischaemic stroke correlate with brain infarct volume, stroke severity and long-term outcome. BMC Neurol. 2004. 4. 2.

41. Emsley H.C., Smith C.J., Gavin C.M. et al. An early and sustained peripheral inflammatory response in acute ischaemic stroke: relationships with infection and atherosclerosis. J. Neuroimmunol. 2003. 139 (1–2). 93-101.

42. Mun-Bryce S., Rosenberg G.A. Matrix metalloproteinases in cerebrovascular disease. J. Cereb. Blood Flow Metab. 1998. 18 (11). 1163-1172.

43. Rosell A., Ortega-Aznar A., Alvarez-Sabán J. et al. Increased brain expression of matrix metalloproteinase-9 after ischemic and hemorrhagic human stroke. Stroke. 2006. 37 (6). 1399-1406.

44. Abilleira S., Montaner J., Molina C.A. et al. Matrix metalloproteinase-9 concentration after spontaneous intracerebral hemorrhage. J. Neurosurg. 2003. 99 (1). 65-70.

45. Vukasovic I., Tesija-Kuna A., Topic E. et al. Matrix metalloproteinases and their inhibitors in different acute stroke subtypes. Clin. Сhem. Lab. Med. 2006. 44. 428-34.

46. Montaner J., Molina C.A., Monasterio J. et al. Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation. 2003. 107. 598-603.

47. Rainer T.H., Wong L.K., Lam W. et al. Prognostic use of circulating plasma nucleic acid concentrations in patients with acute stroke. Clin. Chem. 2003. 49 (4). 562-569.

48. Rainer T.H., Wong K.S., Lam W. et al. Comparison of plasma β-globin DNA and S-100 protein concentrations in acute stroke. Clin. Chim. Acta. 2007. 376 (1–2). 190-196.

49. Di Napoli M., Singh P. Is plasma fibrinogen useful in evaluating ischemic stroke patients? Why, how, and when. Stroke. 2009. 40 (5). 1549-1552.

50. Barber M., Langhorne P., Rumley A. et al. D-dimer predicts early clinical progression in ischemic stroke: confirmation using routine clinical assays. Stroke. 2006. 37 (4). 1113-1115.

51. Delgado P., Alvarez-Sabín J., Abilleira S. et al. Plasma d-dimer predicts poor outcome after acute intracerebral hemorrhage. Neurology. 2006. 67 (1). 94-98.

52. Welsh P., Barber M., Langhorne P. et al. Associations of inflammatory and haemostatic biomarkers with poor outcome in acute ischaemic stroke. Cerebrovasc. Dis. 2009. 27 (3). 247-253.

53. Carter A.M., Catto A.J., Mansfield M.W. et al. Predictive variables for mortality after acute ischemic stroke. Stroke. 2007. 38 (6). 1873-1880.

54. Montaner J., Ribó M., Monasterio J. et al. Thrombin-activable fibrinolysis inhibitor levels in the acute phase of ischemic stroke. Stroke. 2003. 34 (4). 1038-1040.

55. Arenillas J.F., Alvarez-Sabín J., Molina C.A. et al. Progression of symptomatic intracranial large artery atherosclerosis is associated with a proinflammatory state and impaired fibrinolysis. Stroke. 2008. 39 (5). 1456-1463.

56. Ribó M., Montaner J., Molina C.A. et al. Admission fibrinolytic profile predicts clot lysis resistance in stroke patients treated with tissue plasminogen activator. Thromb. Haemost. 2004. 91 (6). 1146-1151.

57. Fernandez-Cadenas I., Alvarez-Sabín J., Ribo M. et al. Influence of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 gene polymorphisms on tissue-type plasminogen activator-induced recanalization in ischemic stroke patients. J. Thromb. Haemost. 2007. 5 (9). 1862-1868.

58. Zalewski A., Nelson J.J., Hegg L. et al. Lp-PLA2: a new kid on the block. Clin. Chem. 2006. 52 (9). 1645e1650.

59. Zalewski A., Macphee C. Role of lipoprotein-associated phospholipase A2 in atherosclerosis: Biology, epidemiology, and possible therapeutic target. Arteriosclerosis, Thrombosis, and Vascular Biology. 2005. Vol. 25, № 5. 923-931.

60. Gorelick P.B. Lipoprotein-associated phospholipase A2 and risk of stroke. Am. J. Cardiol. 2008. 101. 34F-40F.

61. De Stefano A., Mannucci L., Tamburi F. et al. Lp-PLA2, a new biomarker of vascular disorders in metabolic diseases. International Journal of Immunopathology and Pharmacology. 2019. Vol. 33. Article ID 205873841982715.

62. Allard L., Lescuyer P., Burgess J. et al. ApoC-I and ApoC-III as potential plasmatic markers to distinguish between ischemic and hemorrhagic stroke. Proteomics. 2004. 4. 2242-2251.

63. Milionis H.J., Filippatos T.D., Loukas T. et al. Serum lipoprotein(a) levels and apolipoprotein(a) isoform size and risk for first-ever acute ischaemic nonembolic stroke in elderly individuals. Atherosclerosis. 2006 Jul. 187 (1). 170-6. Epub 2005 Sep 28.

64. Allard L., Burkhard P.R., Lescuyer P. et al. PARK7 and nucleoside diphosphate kinase A as plasma markers for the early diagnosis of stroke. Clin. Chem. 2005. 51. 2043-51.

65. Sinha M.K., Gaze D.C., Tippins J.R. et al. Ischemia modified albumin is a sensitive marker of myocardial ischemia after percutaneous coronary intervention. Circulation. 2003. 107 (19). 2403-2405.

66. Gunduz A., Mentese A., Turedi S. et al. Serum ischaemia-modified albumin increases in critical lower limb ischaemia. Emerg. Med. J. 2008. 25 (6). 351-353.

67. Abboud H., Labreuche J., Meseguer E. et al. Ischemia-modified albumin in acute stroke. Cerebrovasc. Dis. 2007. 23 (2–3). 216-220.

68. Chen X., Ba Y., Ma L. et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008. 18. 997-1006.

69. Zhao H., Wang J., Gao L. et al. MiRNA-424 protects against permanent focal cerebral ischemia injury in mice involving suppressing microglia activation. Stroke. 2013. 44. 1706-13.

70. Sepramaniam S., Tan J.R., Tan K.S. et al. Circulating microRNAs as biomarkers of acute stroke. Int. J. Mol. Sci. 2014. 15. 1418-32.

71. Stary C.M., Xu L., Sun X. et al. MicroRNA-200c contributes to injury from transient focal cerebral ischemia by targeting Reelin. Stroke. 2015. 46. 551-6.

72. Van Rooij E., Olson E.N. MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles. Nat. Rev. Drug Discov. 2012. 11. 860-72.

73. Reynolds M.A., Kirchick H.J., Dahlen J.R. et al. Early biomarkers of stroke. Clin. Chem. 2003. 49. 1733-9.

74. Jauch E.C., Lindsell C., Broderick J. et al. Association of serial biochemical markers with acute ischemic stroke: the National Institute of Neurological Disorders and Stroke recombinant tissue plas¬minogen activator Stroke Study. Stroke. 2006. 37. 2508-13.

75. Montaner J., Rovira A., Molina C.A. et al. Plasmatic level of neuroinflammatory markers predict the extent of diffusion-weighted image lesions in hyperacute stroke. J. Cereb. Blood Flow Metab. 2003. 23. 1403-7.  

Similar articles

Authors: Скоромец А.А., Дамбинова С.А., Дьяконов М.М., Гранстрем О.К., Билецкий П.С., Седова О.А., Скоромец А.П., Скоромец Т.А., Смолко Д.Г., Хунтеев Г.В., Шикуев А.В., Шумилина М.В., Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова, академическая группа академика РАМН А.А. Скоромца (Санкт-Петербург, Россия; Университет Эмори, Атланта, США; Сумы, Винница, Украина)
International neurological journal 5(27) 2009
Date: 2010.07.09
Categories: Neurology
Диагностика тяжести ишемического инсульта методом определения уровня маркеров повреждения центральной нервной системы
Authors: Черний В.И., Городник Г.А., Куглер С.Е. - Донецкий национальный медицинский университет им. М. Горького, кафедра анестезиологии, ИТ, МНС и кардиохирургии УНИПО
"Emergency medicine" 3 (58) 2014
Date: 2014.06.18
Categories: Medicine of emergency, Neurology
Sections: Clinical researches
Assessment of the damage to brain tissue by immunoassay in acute ischemic stroke
Authors: Cherny V.I. - Donetsk National Medical University named after M. Gorky, Department of Anesthesiology, intensive care and cardiosurgery
International neurological journal 4 (66) 2014
Date: 2014.08.18
Categories: Neurology
Sections: Specialist manual

Back to issue